Investigators speculate on why infliximab biosimilars don’t have a larger market share by now.
World Health Organization (WHO) prequalification of Celltrion Healthcare’s trastuzumab opens the door for more affordable access to care for patients with breast and gastric cancers.
Although the pandemic continues to affect health care companies worldwide, biosimilar manufacturers continue to move forward with new product developments and business plans.
Vizient predicts that drug price inflation, partly due to the coronavirus disease 2019 (COVID-19), will be 3.29% in 2021 and is banking on biosimilars to help contain the rising cost of medication, it said in a comprehensive review for its member health companies.

On the heels of its earlier announcement of a bevacizumab biosimilar launch, India-based Cadila Pharmaceuticals said it also has a rituximab biosimilar entering the marketplace.
The Center for Biosimilars® spoke with Kashyap B. Patel, MD, about his work in promoting biosimilar uptake and his upcoming book on the importance of living life and not fearing death.
Shanghai Henlius Biotech has been given the green light to market its trastuzumab biosimilar (Zercepac, HLX02) in the European Union. Accord Healthcare will handle the distribution.
If you can’t beat biosimilars, join them, is the mantra; but at Amgen there’s still gold in originator products, according to its latest earnings report.
Biologics are not cheap, and if you can get biosimilars into the hands of patients, you’ve got something going. A strategist describes the step-by-step process that made this possible at Kaiser Permanente.

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.